Effectiveness of duloxetine compared with pregabalin and gabapentin in diabetic peripheral neuropathic pain: Results from a german observational study

Clinical Journal of Pain

Volumn 30, Issue 10, 2014, Pages 875-885

  Happich, Michael ^a   Schneider, Edith ^a   Boess, Frank G ^a   Wilhelm, Stefan ^b   Schacht, Alexander ^a   Birklein, Frank ^c   Ziegler, Dan ^d,e  

^a LILLY DEUTSCHLAND GMBH   (Germany)

^b Fresenius Kabi   (Germany)

^c JOHANNES GUTENBERG UNIVERSITY   (Germany)

^d HEINRICH HEINE UNIVERSITY   (Germany)

^e UNIVERSITY HOSPITAL DÜSSELDORF   (Germany)

Author keywords

Anticonvulsants; DPNP; Duloxetine; Effectiveness; Gabapentin; Noninterventional study; Pregabalin

Indexed keywords

DULOXETINE; GABAPENTIN; PREGABALIN; 4 AMINOBUTYRIC ACID; AMINE; ANALGESIC AGENT; CYCLOHEXANECARBOXYLIC ACID DERIVATIVE; THIOPHENE DERIVATIVE;

ADULT; ARTICLE; BRIEF PAIN INVENTORY; CLINICAL GLOBAL IMPRESSION SCALE; COMPARATIVE EFFECTIVENESS; DIABETIC NEUROPATHY; DIABETIC PERIPHERAL NEUROPATHIC PAIN; DRUG WITHDRAWAL; FEMALE; FOLLOW UP; GERMANY; HEALTH CARE SURVEY; HOSPITAL ANXIETY AND DEPRESSION SCALE; HUMAN; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; MULTICENTER STUDY; NEUROPATHIC PAIN; OBSERVATIONAL STUDY; PAIN SEVERITY; PRIORITY JOURNAL; PROSPECTIVE STUDY; SHEEHAN DISABILITY SCALE; SHORT FORM 12; AGED; ANALOGS AND DERIVATIVES; CHI SQUARE DISTRIBUTION; CLINICAL TRIAL; COMPARATIVE STUDY; DIABETIC NEUROPATHIES; HEALTH SURVEY; PAIN MEASUREMENT; TREATMENT OUTCOME;

AGED; AMINES; ANALGESICS; CHI-SQUARE DISTRIBUTION; CYCLOHEXANECARBOXYLIC ACIDS; DIABETIC NEUROPATHIES; FEMALE; GAMMA-AMINOBUTYRIC ACID; GERMANY; HEALTH SURVEYS; HUMANS; MALE; MIDDLE AGED; PAIN MEASUREMENT; PROSPECTIVE STUDIES; THIOPHENES; TREATMENT OUTCOME;

EID: 84906934937     PISSN: 07498047     EISSN: 15365409     Source Type: Journal    
DOI: 10.1097/AJP.0000000000000057     Document Type: Article

References (45)

1. Tesfaye S, Boulton AJM. Diabetic Neuropathy. Oxford: Oxford University Press; 2009
2. Melton LJ III, Dyck PJ. Diabetic polyneuropathy: epidemiology. In: Dyck PJ, Thomas PK, eds. Diabetic Neuropathy. 2nd ed. Philadelpia: W.B. Saunders; 1999:239-254
3. Tesfaye S, Vileikyte L, Rayman G, et al. On behalf of the Toronto Expert Panel on Diabetic Neuropathy. Painful diabetic peripheral neuropathy: consensus recommendations on diagnosis, assessment and management. Diabetes Metab Res Rev. 2011;27:629-638
4. O'Connor AB, Dworkin RH. Treatment of neuropathic pain: an overview of recent guidelines. Am JMed. 2009;122:S22-S32
5. Attal N, Gruccu G, Baron R, et al. European Federation of Neurological Societies. EFNS guidelines on the pharmacological treatment of neuropathic pain: 2010 revision. Eur J Neurol. 2010;17:1113-1123
6. NICE guideline. Neuropathic pain-pharmacological management, CG96; 2012. Available at: http://www.nice.org.uk/guidance/CG96. Accessed November 2013.
7. Quilici S, Chancellor J, Löthgren M, et al. Meta-Analysis of duloxetine vs. pregabalin and gabapentin in the treatment of diabetic peripheral neuropathic pain. BMC Neurol. 2009;9:6
8. Boyle J, Eriksson ME, Gribble L, et al. Randomized, placebocontrolled comparison of amitriptyline, duloxetine, and pregabalin in patients with chronic diabetic peripheral neuropathic pain: impact on pain, polysomnographic sleep, daytime functioning, and quality of life. Diabetes Care. 2012; 35:2451-2458
9. Kaur H, Hota D, Bhansali A, et al. A comparative evaluation of amitriptyline and duloxetine in painful diabetic neuropathy: a randomized, double-blind, cross-over clinical trial. Diabetes Care. 2011;34:818-822
10. Tanenberg RJ, Irving GA, Risser RC, et al. Duloxetine, pregabalin, and duloxetine plus gabapentin for diabetic peripheral neuropathic pain management in patients with inadequate pain response to gabapentin: an open-label, randomized, non-inferiority comparison. Mayo Clin Proc. 2011;86:615-626
11. Tesfaye S, Wilhelm S, Lledo A, et al. Duloxetine and pregabalin: high-dose monotherapy or their combination? The "COMBO-DN study"-A multinational, randomized, double-blind, parallel-group study in patients with diabetic peripheral neuropathic pain. Pain. 2013;154:2616-2625
12. Baron R. Detection and treatment of neuropathic pain syndromes. Dtsch Arztebl. 2006;103:A2720-A2730
13. Wallace JM. Update on pharmacotherapy guidelines for treatment of neuropathic pain. Curr Pain Headache Rep. 2007; 11:208-214
14. Schneider E, Ziegler D, Wilhelm S, et al. Patient expectations and physicians' judgment in the treatment of diabetic peripheral neuropathic pain. Poster presented at EFIC congress, 2011, Hamburg, Germany; #524. EJP Supplements 5. 2011;15-25. (T266)
15. Ziegler D. Current concepts in the management of diabetic polyneuropathy. Curr Diabetes Rev. 2011;7:208-220
16. Hall JA, Wang F, Oakes TM, et al. Safety and tolerability of duloxetine in the acute management of diabetic peripheral neuropathic pain: analysis of pooled data from three placebocontrolled clinical trials. Expert Opin Drug Saf. 2010;9: 525-537
17. Summary of product characteristics duloxetine, date of revision of the text: 26/07/2011. Available at: http://www. medicines.org.uk/emc/medicine/15694. Accessed November 21, 2012
18. Summary of product characteristics gabapentine, date of revision of the text 11/2010. Available at: http://www. medicines.org.uk/EMC/medicine/25430/SPC/Gabapentin+100 +mg+Capsules/. Accessed November 21, 2012
19. Summary of product characteristics pregabaline, date of revision of the text 11/2011. Available at: http://www.medicines.org.uk/EMC/medicine/26524/SPC/LYRICA+20+mg+ml+oral+solution/. Accessed November 21, 2012
20. Freeman R, Durso-Decruz E, Emir B. Efficacy, safety, and tolerability of pregabalin treatment for painful diabetic peripheral neuropathy: findings from seven randomized, controlled trials across a range of doses. Diabetes Care. 2008; 31:1448-1454
21. Pritchett YL, McCarberg BH, Watkin JG, et al. Duloxetine for the management of diabetic peripheral neuropathic pain: response profile. Pain Med. 2007;8:397-409
22. Moore RA, Straube S, Wiffen PJ, et al. Pregabalin for acute and chronic pain in adults. Cochrane Database Syst Rev. 2009; CD007076
23. Cleeland CS, Ryan KM. Pain assessment: global use of the Brief Pain Inventory. Ann Acad Med Singapore. 1994;23:129-138
24. Zigmond AS, Snaith RP. The Hospital Anxiety and Depression Scale. Acta Psychiatr Scand. 1983;67:361-370
25. Guy W. ECDEU Assessment Manual for Psychopharmacology-Revised. Rockville, MD: National Institute of Mental Health, Psychopharmacology Research Branch; 1976:218-222
26. Sheehan DF. Sheehan Disability Scale. In: Rush AJ Jr, Pincus HA, First MB, Blacker D, Endicott J, Keith SJ, Phillips KA, Ryan ND, Smith GR Jr, Tsuang MT, Widiger TA, Zarin DA, eds. Handbook of Psychiatric Measures by American Psychiatric Association.Task force for the Handbook of Psychiatric Measures.2000: Washington, DC: APA; 1983:113-115
27. Ware J Jr, Kosinski M, Keller SD. A 12-Item Short-Form Health Survey: construction of scales and preliminary tests of reliability and validity. Med Care. 1996;34:220-233
28. D'Agostino RB. Propensity score methods for bias reduction in the comparison of a treatment to a non-randomized control group. Stat Med. 1998;17:2265-2281
29. Beers MH. Explicit criteria for determining potentially inappropriate medication use by the elderly. An update. Arch Intern Med. 1997;157:1531-1536
30. Fick DM, Cooper JW, Wade WE, et al. Updating the Beers criteria for potentially inappropriate medication use in older adult: results of a US consensus panel of experts. Arch Intern Med. 2003;163:2716-2724
31. Laroche ML, Charmes JP, Bouthier F, et al. Inappropriate medications in the elderly. Clin Pharmacol Ther. 2009;85: 94-97
32. Holt S, Schmiedl S, Thürmann PA. Potentially inappropriate medications in the elderly: the PRISCUS list. Dtsch Arztebl Int. 2010;107:543-551
33. Backonja M, Beydoun A, Edwards KR, et al. Gabapentin for the symptomatic treatment of painful neuropathy in patients with diabetes mellitus: a randomized controlled trial. JAMA. 1998;280:1831-1836
34. Toelle TR, Varvara R, Nimour M, et al. Pregabalin in neuropathic pain related to DPN, Cancer and Back Pain. Analysis of a 6-week observational study. Open Pain J. 2012; 5:1-11
35. Mallison R, Tilke C, Brasser M, et al. Efficacy and tolerability of pregabalin in patients with neuropathic pain. Observational study under clinical practice conditions. MMW Fortschr Med. 2007;149:46
36. Härmark L, van Puijenbroek E, Straus S, et al. Intensive monitoring of pregabalin: results from an observational, webbased, prospective cohort study in the Netherlands using patients as a source of information. Drug Saf. 2011;34:221-231
37. Sun P, Zhao Y, Zhao Z, et al. Dosing pattern comparison between duloxetine and pregabalin among patients with diabetic peripheral neuropathic pain. Pain Pract. 2012;12: 641-648
38. Goldstein DJ, Lu Y, Detke MJ, et al. Duloxetine vs. placebo in patients with painful diabetic neuropathy. Pain. 2005;116: 109-118
39. Raskin J, Pritchett YL, Wang F, et al. A double-blind, randomized multicenter trial comparing duloxetine with placebo in the management of diabetic peripheral neuropathic pain. Pain Med. 2005;6:346-356
40. Wernicke JF, Pritchett YL, D'Souza DN, et al. A randomized controlled trial of duloxetine in diabetic peripheral neuropathic pain. Neurology. 2006;67:1411-1420
41. Goldney RD, Phillips PJ, Fisher LJ, et al. Diabetes, depression, and quality of life: a population study. Diabetes Care. 2004;27:1066-1070
42. Al-Ghamdi AA. A high prevalence of depression among diabetic patients at a teaching hospital in Western Saudi Arabia. Neurosciences. 2004;9:108-112
43. Silva N, Atlantis E, Ismail K. A review of the association between depression and insulin resistance: pitfalls of secondary analyses or a promising new approach to prevention of type 2 diabetes? Curr Psychiatry Rep. 2012;14:8-14
44. Spallone V. Management of painful diabetic neuropathy: guideline guidance or jungle? Curr Diab Rep. 2012;12:403-413
45. Pergolizzi JF Jr, Raffa RB, Taylor R Jr, et al. A review of duloxetine 60mg once-daily dosing for the management of diabetic peripheral neuropathic pain, fibromyalgia, and chronic musculoskeletal pain due to chronic osteoarthritis pain and low back pain. Pain Pract. 2013;13:239-252.